Categories : Endocrine & Metabolic
Product Packaging : 10 / 30 tablets
Product Composition : 2 mg + 500 mg + 0.2 mg, 2 mg + 500 mg + 0.3 mg
Send MessageGlimepiride + Metformin SR + Voglibose Tablets are a comprehensive triple-drug antidiabetic formulation designed to address multiple pathophysiological aspects of type 2 diabetes mellitus. This advanced combination integrates Glimepiride to stimulate pancreatic insulin secretion, Metformin SR to reduce hepatic glucose output and improve insulin sensitivity, and Voglibose, an alpha-glucosidase inhibitor that delays carbohydrate absorption in the intestine.
The sustained-release (SR) matrix of Metformin ensures prolonged therapeutic activity, while Voglibose specifically targets postprandial hyperglycemia, making this combination highly effective for patients with fluctuating glucose levels after meals. This triple therapy is widely used in cases where dual therapy fails to achieve adequate glycemic control.
Genliva Wellness LLP, Himatnagar, India, is a reliable glimepiride metformin voglibose tablet manufacturer India, delivering globally compliant formulations tailored for pharmaceutical distributors, hospitals, and contract manufacturing partners.
Glimepiride + Metformin SR + Voglibose Tablets are triple-combination antidiabetic medications formulated to provide comprehensive blood glucose management in type 2 diabetes mellitus. The sustained-release formulation supports prolonged glycemic control and improved metabolic balance.
These tablets are commonly used for the management of type 2 diabetes mellitus in adults when dual therapy is insufficient. They help improve glycemic control along with diet and exercise support.
Glimepiride + Metformin SR + Voglibose Tablets provide multi-targeted glucose control with enhanced metabolic support and patient convenience for effective diabetes care.
